Form 4: EyePoint Pharmaceuticals Director Exercises Stock Options
SEC Form 4
Karen L. Zaderej, a director at EyePoint Pharmaceuticals, exercised stock options and converted restricted stock units into common stock on July 11, 2024.
Summary
- On July 11, 2024, Karen L. Zaderej, a director of EyePoint Pharmaceuticals, exercised options to acquire 2,000 shares of common stock.
- The transaction also involved the conversion of 2,000 restricted stock units into common stock.
- Following these transactions, Ms. Zaderej directly owns 4,000 shares of EyePoint Pharmaceuticals common stock and 2,000 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions and provides transparency to the market regarding the holdings of company directors.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 07/11/2023 | Beginning of the vesting period for the restricted stock units in three ratable annual installments. |
| 07/11/2024 | Date of transaction: Exercise of stock options and conversion of restricted stock units. |
| 07/12/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.